Skip to main content
. 2017 Jan 10;2017:9261351. doi: 10.1155/2017/9261351

Table 3.

Thrombosis medical profile and antepartum prophylactic use of AT concentrate in pregnant patients with hereditary antithrombin deficiency.

Study Study design Number of cases Prophylactic condition and numbers of cases Dosage of AT used Concurrent anticoagulation AT concentrate initiation/duration Goal of AT levels Outcome
Primary Secondary
Ilonczai et al.
2015
Retrospective 4 2 2 1000–2500
2tw-3tw
LMWH Primary, gw 11–28;
       gw 20–36
Secondary, gw 6–13;
      gw 25–29
80–120% Miscarriage gw 28
Healthy M and N
Miscarriage gw 3
Healthy M and N

Rogenhofer et al. (2014) Retrospective 4 1 3 1000 2tw- 2500 IU 3tw
LMWH Primary, 3 days as initiation of LMWH at early pregnancy to delivery
Secondary, gw 6, 7, 34 to delivery
N/A Healthy M and N

Pascual et al.
(2014)
Case report 1 1 3000 IU
3tw
LMWH, UFH then warfarin at 14 wk gw 4–15 and 11 days peripartum >50% Healthy M and N

Yamada et al.
(2001)
Case report 1 1 3000–6000 IU
weekly
N/A gw 5–38 80–90% Healthy M and N

AT: antithrombin, gw: gestational week, IU: international units, LMWH: low molecular weight heparin, M: mother, N/A: not available or not specified, N: newborn, UFH: unfractionated heparin, gw: gestational week, IU: international units, IVC: inferior vena cava, UFH: unfractionated heparin, 2tw: two times per week, and 3tw: three times per week.